Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Thursday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Trading Down 1.1 %

Shares of ADXS opened at $0.89 on Thursday. Ayala Pharmaceuticals has a 52-week low of $0.65 and a 52-week high of $3.75. The business’s fifty day moving average is $0.92 and its 200-day moving average is $0.99.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.